argenx Appoints Karl Gubitz as Chief Financial Officer
01 Giugno 2021 - 10:01AM
June 1, 2021Breda, the
Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases and cancer, today
announced the appointment of Mr. Karl Gubitz as Chief Financial
Officer. Mr. Gubitz brings to argenx nearly 20 years of global
pharmaceutical leadership experience, specifically in financial
planning and analysis, business partnerships and product
commercialization. He will succeed Eric Castaldi, who will remain
with the company through June 30, 2021.
“We are delighted to welcome Karl to our
executive leadership team as he has an impressive track record of
successfully establishing commercial organizations and providing
strategic financial direction for global biopharmaceutical
companies,” said Tim Van Hauwermeiren, CEO of argenx. “Karl’s
insight and financial expertise will make him an indispensable
member of the team as we advance our vision of developing an
integrated, innovative, global immunology organization that aims to
impact the lives of patients.”
“On behalf of the argenx management team and
Board of Directors, we thank Eric for his significant contributions
as we have grown from a private company to a near-commercial
organization. It has been a pleasure working with him and we are
grateful for the integral role he played in our growth and success
over the last seven years. He will always be a part of the argenx
family and we wish him well in all his future ventures,” added Mr.
Van Hauwermeiren.
Mr. Gubitz has nearly 20 years of experience as
a senior finance professional in the pharmaceutical industry at
Pfizer, where he most recently served as Vice President of Finance
within the Global Oncology business. At Pfizer, he successfully
negotiated the commercialization model for tanezumab with Eli Lilly
in all non-U.S. markets as well as the Myovant co-commercialization
agreement for Orgovyx™. Within Pfizer, Mr. Gubitz has held country,
regional, and global positions, and consistently delivered top-line
growth. He has managed teams of over 250 colleagues in roles such
as Vice President of Finance in the Global Internal Medicine
business and Vice President of Finance, North America in the Global
Innovative Products business. Prior to joining Pfizer in 2003, Mr.
Gubitz held various management roles at PricewaterhouseCoopers. Mr.
Gubitz holds a Master of Business Administration from Henley
Management College in the United Kingdom, a Bachelor of Computing
from the University of South Africa, and a Bachelor of Commerce
from the University of Pretoria.
“This is a particularly exciting time to be
joining argenx, as the Company nears the first potential commercial
launch of its lead product, efgartigimod,” said Mr. Gubitz. “I look
forward to working alongside this talented team as we transition to
a commercial-stage company and grow argenx’s global immunology
footprint to improve the lives of patients suffering from a variety
of autoimmune diseases.”
About argenx
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune
diseases and cancer. Partnering with leading academic researchers
through its Immunology Innovation Program (IIP), argenx aims to
translate immunology breakthroughs into a world-class portfolio of
novel antibody-based medicines. argenx is evaluating efgartigimod
in multiple serious autoimmune diseases, and cusatuzumab in
hematological cancers in collaboration with Janssen. argenx is also
advancing several earlier stage experimental medicines within its
therapeutic franchises. argenx has offices in Belgium, the United
States, Japan, and Switzerland. For more information, visit
www.argenx.com and follow us on LinkedIn at
https://www.linkedin.com/company/argenx/ and Twitter at
https://twitter.com/argenxglobal.
For further information, please contact:
Media:
Kelsey Kirkkkirk@argenx.com
Joke Comijn jcomijn@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Forward-looking Statements
The contents of this announcement include
statements that are, or may be deemed to be, “forward-looking
statements.” These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“believes,” “estimates,” “anticipates,” “expects,” “intends,”
“may,” “will,” or “should” and include statements argenx makes
concerning its commercial readiness; its hope to reach
patients this year; its statements regarding the therapeutic
potential of Efgartigimod in patients; 2021 business and financial
outlook and related plans; the therapeutic potential of its product
candidates; the intended results of its strategy and argenx’s, and
its collaboration partners’, advancement of, and anticipated
clinical development, data readouts and regulatory milestones and
plans, including the timing of planned clinical trials and expected
data readouts; the design of future clinical trials and the timing
and outcome of regulatory filings and regulatory approvals. By
their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. argenx’s actual results may differ materially from
those predicted by the forward-looking statements as a result of
various important factors, including the effects of the COVID-19
pandemic, argenx’s expectations regarding its the inherent
uncertainties associated with competitive developments, preclinical
and clinical trial and product development activities and
regulatory approval requirements; argenx’s reliance on
collaborations with third parties; estimating the commercial
potential of argenx’s product candidates; argenx’s ability to
obtain and maintain protection of intellectual property for its
technologies and drugs; argenx’s limited operating history; and
argenx’s ability to obtain additional funding for operations and to
complete the development and commercialization of its product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in argenx’s U.S.
Securities and Exchange Commission (SEC) filings and reports,
including in argenx’s most recent annual report on Form 20-F
filed with the SEC as well as subsequent filings and reports filed
by argenx with the SEC. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. argenx undertakes no
obligation to publicly update or revise the information in this
press release, including any forward-looking statements, except as
may be required by law.
Grafico Azioni Argen X (EU:ARGX)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Argen X (EU:ARGX)
Storico
Da Apr 2023 a Apr 2024